| Literature DB >> 32542176 |
Farouk Nouizi1, Jamison Brooks2,3, Darren M Zuro2,3, Srideshikan Sargur Madabushi2, Dayson Moreira4, Marcin Kortylewski4, Jerry Froelich5, Lydia M Su1, Gultekin Gulsen1, Susanta K Hui2.
Abstract
Hypofractionated stereotactic body radiotherapy treatments (SBRT) have demonstrated impressive results for the treatment of a variety of solid tumors. The role of tumor supporting vasculature damage in treatment outcome for SBRT has been intensely debated and studied. Fast, non-invasive, longitudinal assessments of tumor vasculature would allow for thorough investigations of vascular changes correlated with SBRT treatment response. In this paper, we present a novel theranostic system which incorporates a fluorescence molecular imager into a commercial, preclinical, microCT-guided, irradiator and was designed to quantify tumor vascular response (TVR) to targeted radiotherapy. This system overcomes the limitations of single-timepoint imaging modalities by longitudinally assessing spatiotemporal differences in intravenously-injected ICG kinetics in tumors before and after high-dose radiation. Changes in ICG kinetics were rapidly quantified by principle component (PC) analysis before and two days after 10 Gy targeted tumor irradiation. A classifier algorithm based on PC data clustering identified pixels with TVR. Results show that two days after treatment, a significant delay in ICG clearance as measured by exponential decay (40.5±16.1% P=0.0405 Paired t-test n=4) was observed. Changes in the mean normalized first and second PC feature pixel values (PC1 & PC2) were found (P=0.0559, 0.0432 paired t-test), suggesting PC based analysis accurately detects changes in ICG kinetics. The PC based classification algorithm yielded spatially-resolved TVR maps. Our first-of-its-kind theranostic system, allowing automated assessment of TVR to SBRT, will be used to better understand the role of tumor perfusion in metastasis and local control.Entities:
Keywords: Fluorescence Molecular Imaging; Pharmacokinetics; Preclinical Imaging; Principal Component Analysis; Radiation Therapy; Stereotactic Body Radiotherapy Treatments; Theranostics; Tumor Vascular Response
Year: 2020 PMID: 32542176 PMCID: PMC7295127 DOI: 10.1109/access.2020.2994943
Source DB: PubMed Journal: IEEE Access ISSN: 2169-3536 Impact factor: 3.367